Stocks · News reference

Lakefront Biotherapeutics Says FDA Granted Orphan Drug Designation To Gamgertamig For Treatment Of Pemphigus

Aug 24, 2026, 8:02 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 24, 2026, 8:02 PMBenzinga Newsdesk
Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11%
Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America.Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from
Read original at benzinga
BAC LKFT
BenzingaAug 11, 2026, 3:57 PMBenzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.
Read original at benzinga
LKFT
BenzingaAug 11, 2026, 3:20 PMBenzinga Newsdesk
RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26
RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.
Read original at benzinga
LKFT